About us

Belgium-based biotech company

Founded in 2018, Dendrogenix develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology

2000
Dendrogenix is founded
0
Patents Family
0
Partners
6500
Cups of Coffee

Technology

The origin of the discovery of our Dendrogenins results from the study of tamoxifen's mode of action through functional genomics studies. Tamoxifen has been the first drug used to treat hormone-dependent breast cancer. During metabolic and functional genomics studies associated with the activity of this drug, an ancillary pathway for Tamoxifen which is involved in the control of cell differentiation has been identified by Dr. Marc Poirot and his scientific team at the INSERM Institute in Toulouse. This pathway is based on serial sterol metabolism that generates molecules with original structures called Dendrogenins. These molecules stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors.

Our Team

We stay on top of our industry by being experts.

Board of Directors

Emile LORIA
MD

CHAIRMAN OF THE BOARD

Patrick STRAGIER (PhD)

NOSHAQ SPIN-OFFS REPRESENTATIVE

Caroline THIELEN (PhD)

SRIW REPRESENTATIVE

Partners

Contact

B34 +3 CHU de Liège

Avenue de l’Hôpital, 11
GIGA B34 +3
B4000 Liège
Belgium

Email: contact@dendrogenix.com